First-in-human trial of AB-1002 designed to establish safety and preliminary efficacy in patients with NYHA Class III Heart Failure Heart failure is a leading cause of morbidity and mortality worldwide despite available therapies, and quality of life is poor1 It is estimated 26 million…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.